Optimise viewing for

Toggle between patient and health professional views. The patient version is simplified to help people easily find suitable trials, while the professional view provides full detail.

No longer recruiting (closed or complete)Last updated: 4 April 2025

EURONET-PHL-C2: This phase III trial is evaluating chemotherapy intensification in Hodgkin Lymphoma patients who receive less radiotherapySecond International Inter-Group Study for Classical Hodgkin Lymphoma in Children and Adolescents

Trial purpose

Medical clipboardCancer treatment

Tumor type

Blood Cancers Haematological

Age

People0 - 25

Trial acronym

EURONET-PHL-C2

Clinical summary

Summary

The EuroNet-PHL-C2 trial is an international, multicentre, randomised controlled trial with the aims to reduce the indication for radiotherapy in newly diagnosed patients with classical Hodgkin lymphoma without compromising cure rates and to investigate a chemotherapy intensification randomisation in intermediate and advanced classical Hodgkin lymphoma to compensate for reduction in radiotherapy.

Conditions

This trial is treating people with Hodgkin's Disease (Hodgkin's Lymphoma)

Eligibility

Inclusion

  • histologically confirmed primary diagnosis of classical Hodgkin's lymphoma
  • patients under 18 years of age on the date of written informed consent. In specialized Teenage and Young Adult (TYA) units in France, Italy and UK patients up to under 25 years of age can also be enrolled. Lower age limits will be country specific according to national laws or formal insurance requirements that may preclude very young patients.
  • written informed consent of the patient and/or the patient's parents or guardian according to national laws
  • negative pregnancy test within 2 weeks prior to starting treatment for female patients with childbearing potential

Exclusion

  • prior chemotherapy or radiotherapy for other malignancies
  • pre-treatment of Hodgkin's lymphoma (except for 7-10 days steroid pre-phase of a large mediastinal tumour)
  • diagnosis of lymphocyte-predominant Hodgkin's lymphoma
  • other (simultaneous) malignancies
  • contraindication or known hypersensitivity to study drugs
  • severe concomitant diseases (e.g. immune deficiency syndrome)
  • known HIV-positivity
  • residence outside the participating countries where long term follow-up cannot be guaranteed
  • pregnancy and/or lactation
  • patients who are sexually active and are unwilling to use adequate contraception during therapy and for one month after last trial treatment
  • current or recent (within 30 days prior to date of written informed consent) treatment with another investigational drug or participation in another interventional clinical trial

Inclusion

  • You have been diagnosed with cancer, but have not received any treatment.

Exclusion

  • You have been diagnosed with a prior or secondary type of cancer.
  • You have certain types of non-cancer medical conditions.
  • You have had certain treatments, surgical procedures or drugs.
Message

Clinical trials have complex eligibility criteria, and other criteria may apply for this trial. Ask your doctor about whether this trial could be right for you.

Participating hospitals

+ Show non-recruiting hospitals

No longer recruiting (closed or complete) hospitals

InformationTell us if you find this trial availability is not accurate.Report inaccuracy

More information

Trial Identifiers

Information on this page is partially produced from ClinicalTrials.gov *. View further details about this trial on the registry via the links below:

Trial sponsor

Royal Children's Hospital

Scientific Title

Second International Inter-Group Study for Classical Hodgkin Lymphoma in Children and Adolescents

Get Support

Cancer Connect

You might find it helpful to speak to someone who has 'been there before'. Our Cancer Connect program can provide one-on-one phone support from someone who understands what you're going through and has clinical trials experience.

Know more about Cancer Connect

Cancer Council’s cancer nurses

If you need cancer information and practical support for yourself, a carer, family or friend, contact Cancer Council’s experienced cancer nurses on 131120.

Get support

Multilingual information

Learn more about clinical trials through this collection of resources in languages other than English.

View information